The latest cohort of companies have joined the Venture Lab acceleration programme for early-stage companies, created by non-profit foundation the BioInnovation Institute (BII).
Designed to help build research-based ideas with high-growth commercial potential into viable start-ups, BII’s 12-month Venture Lab programme supports business acceleration, scientific and team development. It provides a risk-free convertible loan of €0.5 million plus access to labs and offices in Copenhagen. Companies can also apply for up to €1.3 million through BII’s new Venture House programme.
New companies include: HHC Medical, Fimmcyte and Ebumab, plus IVJector and D’ChangO (corporate sponsored projects from Novo Nordisk).
Bobby Soni, Chief Business Officer at BioInnovation Institute, said: “We look forward to supporting them with the many aspects of development needed to deliver first-in-class science that will positively impact global health and the environment.”
Assisted by a dedicated scientific advisor, a leadership coach and a BII business development expert, the new ventures will be guided in developing a detailed milestone plan and will be assisted in overcoming the challenges of growing a business.
BII has so far supported 62 start-ups and projects. Recent success stories include Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.
